Clinical trials: Advanced Solid Malignancy
Cachexia, Unspecified Adult Solid Tumor, Protocol Specific
Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors
RATIONALE: Adenosine triphosphate may decrease weight loss and improve muscle strength in patients with advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of adenosine triphosphate in controlling loss of…
- Trial name
- NCT00014248
- Testing
- adenosine triphosphate, quality-of-life assessment
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Solid Tumors, Neuroendocrine Tumors
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients…
- Conditions
- Solid Tumors, Neuroendocrine Tumors, CRC
- Trial name
- NCT05167071
- Testing
- HBM4003, Toripalimab, Tislelizumab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
Advanced Solid Tumor
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.
- Trial name
- NCT05911464
- Testing
- HS-10386
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with…
- Trial name
- NCT03099109
- Testing
- LY3321367, LY3300054
- Where
- 15 sites in United States, Japan and 2 more
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
Iso-fludelone is a type of chemotherapy drug called an epothilone. Epothilones are drugs that attach to proteins in your body called "tubulins". Tubulins help cells to grow, and are found in both normal and cancer cells.
- Trial name
- NCT01379287
- Testing
- Iso-Fludelone
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Solid Tumor, Solid Tumor, Adult
Psychotherapy Intervention for Latinos With Adv Cancer
The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones.
- Conditions
- Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04537936
- Testing
- Meaning Centered Psychotherapy for Latinos, Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale, Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Refractory Solid Tumors
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors
- Trial name
- NCT04892498
- Testing
- Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF
- Where
- 16 sites in China
- Volunteers
- 66 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and…
- Trial name
- NCT06311214
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 29 sites in United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.
- Trial name
- NCT00708006
- Testing
- HGS1029
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Human Genome Sciences Inc.
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumor
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors.
- Trial name
- NCT07327632
- Testing
- IBI3026
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Lung Cancer, Non-Small Cell Lung Cancer
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors.
- Trial name
- NCT00826449
- Testing
- Dasatinib, Erlotinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor
CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor
This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibodies (CTLA-4 and PD-1) and chimeric antigen…
- Trial name
- NCT03179007
- Testing
- Anti-CTLA-4/PD-1 expressing MUC1-CAR-T
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Cell Therapy Research Institute
Neoplasms
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK)…
- Trial name
- NCT03190811
- Testing
- Anti-PD-1 plus DC-CIK, Anti-PD-1 alone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Capital Medical University
Advanced Malignant Solid Tumor
Phase I/II Study of SCTB39G in Advanced Solid Tumours
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours.
- Trial name
- NCT07077252
- Testing
- SCTB39G
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sinocelltech Ltd.
Neoplasms
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to…
- Trial name
- NCT00088647
- Testing
- MST-997
- Where
- 3 sites in United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cancer, Advanced Solid Tumors
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors.
- Conditions
- Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
- Trial name
- NCT03893955
- Testing
- ABBV-927, ABBV-368, ABBV-181
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.